Y0001272

齐拉西酮

European Pharmacopoeia (EP) Reference Standard

• 别名: 齐拉西酮 盐酸盐 一水合物, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one 盐酸盐 一水合物, CP-88059, Geodon
• 经验公式（希尔记法）: C₂₁H₂₁ClN₄OS · HCl · H₂O
• CAS号: 138982-67-9
• 分子量: 467.41
• MDL號碼: MFCD00921885
• 分類程式碼代碼: 41116107
• PubChem物質ID: 329831335
• NACRES: NA.24

属性

• 等級: pharmaceutical primary standard
• API 家族: ziprasidone
• 製造商／商標名: EDQM
• 應用: pharmaceutical (small molecule)
• 格式: neat
• 儲存溫度: 2-8°C
• SMILES 字串: O.Cl.Clc1cc2NC(=O)Cc2cc1CCN3CCN(CC3)c4nsc5ccccc45
• InChI: 1S/C21H21ClN4OS.ClH.H2O/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21;;/h1-4,11,13H,5-10,12H2,(H,23,27);1H;1H2
• InChI 密鑰: ZCBZSCBNOOIHFP-UHFFFAOYSA-N
• 基因資訊: human ... DRD2(1813) , HTR2A(3356) , HTR2C(3358)

说明

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Ziprasidone for system suitability 1 EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化／生理作用

Ziprasidone is an atypical antipsychotic; FDA approved for the treatment of schizophrenia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

安全信息

• 象形圖: GHS08,GHS07
• 訊號詞: Warning
• 危險聲明: H317,H373
• 防範說明: P260 - P280
• 危險分類: Skin Sens. 1 - STOT RE 2 Oral
• 標靶器官: Liver,Central nervous system
• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable